Status:
TERMINATED
Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy
Lead Sponsor:
Institut Cancerologie de l'Ouest
Conditions:
Glial Tumor
Eligibility:
All Genders
Phase:
NA
Brief Summary
Patients with brain tumours experience a loss of independence, which may occur suddenly or gradually. Communication with the patient may be rapidly impaired, due to impaired alertness, language and/or...
Eligibility Criteria
Inclusion
- Patients with histologically proven grade III and IV glial tumours requiring speech therapy;
- Patient willing to start outpatient speech therapy;
- Patient aged 18 years and over;
- Informed patient who has signed consent;
- Patient affiliated to a social security scheme.
Exclusion
- Patient who has already had an initiation to sophrology in the context of his pathology;
- PS ≥ 4 ;
- Patients suffering from psychiatric disorders; delusional phases, schizophrenia against the practice of sophrology;
- Patient unable to follow the protocol (filling in questionnaires, attendance of sophrology and/or speech therapy sessions) for geographical, social or psychological reasons;
- Patients who do not speak French;
- Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian.
- Women who are pregnant, likely to be pregnant or breastfeeding;
Key Trial Info
Start Date :
October 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 5 2024
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT05189366
Start Date
October 17 2022
End Date
November 5 2024
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de Cancérologie de l'Ouest
Saint-Herblain, France, 44805